Read the original article here. Halifax-based Panag Pharma, which is making pain-relief products from natural compounds found in cannabis plants, has agreed to be bought for as much as $27 million by Ontario’s Tetra Bio-Pharma. Based in the Ottawa suburb of Orleans, Tetra is a drug discovery company that specializes in developing treatments based on such compounds – known as cannabinoid-based drug discovery. The company, which is listed on the TSX Venture Exchange, said in a press release that the acquisition will allow Tetra to develop more natural healthcare products and sell them world wide. The Panag Team – which is led by healthcare professionals Mary Lynch, Melanie Kelly and Orlando Hung – will continue to conduct research into cannabinoid-based treatments for Tetra, and receive extra payments for hitting specific milestones. The buyer said it believes it will gain revenues from Panag’s products by late 2019. Continue reading]]>
Recent Posts
- ENTREVESTOR: IMV Inc. entering a crucial phase in late 2019
- Mallinckrodt Agrees to Sell BioVectra Inc. to H.I.G. Capital for $250 Million
- IMV Announces Research Collaboration with The Wistar Institute to Develop New Targeted Immunotherapy Against the Common BRAF Cancer Mutation
- ACOA NEWS RELEASE: Panag Pharma providing effective, non-addictive plant-based pain management
- Entrevestor: Motryx Wins $100K Women’s Fund Grant